Retirement Systems of Alabama raised its position in United Therapeutics Corporation (NASDAQ:UTHR) by 0.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 83,291 shares of the biotechnology company’s stock after buying an additional 44 shares during the period. Retirement Systems of Alabama’s holdings in United Therapeutics Corporation were worth $10,805,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the company. BlackRock Inc. increased its position in shares of United Therapeutics Corporation by 4,222.8% in the first quarter. BlackRock Inc. now owns 4,741,985 shares of the biotechnology company’s stock worth $641,969,000 after buying an additional 4,632,287 shares during the period. FMR LLC increased its position in shares of United Therapeutics Corporation by 2.4% in the first quarter. FMR LLC now owns 4,138,779 shares of the biotechnology company’s stock worth $560,308,000 after buying an additional 98,529 shares during the period. Vanguard Group Inc. increased its position in shares of United Therapeutics Corporation by 7.3% in the first quarter. Vanguard Group Inc. now owns 3,785,099 shares of the biotechnology company’s stock worth $512,427,000 after buying an additional 256,514 shares during the period. State Street Corp increased its position in shares of United Therapeutics Corporation by 7.6% in the first quarter. State Street Corp now owns 1,997,327 shares of the biotechnology company’s stock worth $270,411,000 after buying an additional 140,949 shares during the period. Finally, Palo Alto Investors LLC increased its position in shares of United Therapeutics Corporation by 0.8% in the first quarter. Palo Alto Investors LLC now owns 1,883,315 shares of the biotechnology company’s stock worth $254,963,000 after buying an additional 14,500 shares during the period.

Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at 127.02 on Friday. The company has a market cap of $5.52 billion, a PE ratio of 14.73 and a beta of 1.51. The stock’s 50 day moving average price is $130.70 and its 200-day moving average price is $135.52. United Therapeutics Corporation has a one year low of $110.90 and a one year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings results on Thursday, July 27th. The biotechnology company reported ($1.25) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.61 by $4.86. United Therapeutics Corporation had a return on equity of 20.96% and a net margin of 24.18%. The company had revenue of $444.60 million for the quarter, compared to analysts’ expectations of $391.53 million. During the same quarter in the previous year, the business earned $4.42 EPS. The company’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, analysts expect that United Therapeutics Corporation will post $13.33 EPS for the current year.

United Therapeutics Corporation declared that its board has approved a stock buyback program on Thursday, April 27th that allows the company to repurchase $250.00 million in shares. This repurchase authorization allows the biotechnology company to purchase up to 4.6% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.

ILLEGAL ACTIVITY WARNING: “United Therapeutics Corporation (UTHR) Stake Boosted by Retirement Systems of Alabama” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/united-therapeutics-corporation-uthr-stake-boosted-by-retirement-systems-of-alabama/1472936.html.

A number of equities analysts have weighed in on UTHR shares. Zacks Investment Research downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Thursday, July 13th. BidaskClub downgraded United Therapeutics Corporation from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. ValuEngine raised United Therapeutics Corporation from a “buy” rating to a “strong-buy” rating in a research report on Thursday, July 13th. Wedbush reissued an “outperform” rating and set a $213.00 price target (down previously from $229.00) on shares of United Therapeutics Corporation in a research report on Thursday, April 27th. Finally, UBS AG reissued a “sell” rating and set a $106.00 price target on shares of United Therapeutics Corporation in a research report on Thursday, July 6th. Six analysts have rated the stock with a sell rating, seven have given a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $134.50.

In other news, CEO Martine A. Rothblatt sold 1,265 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The shares were sold at an average price of $119.40, for a total transaction of $151,041.00. Following the completion of the sale, the chief executive officer now owns 1,405 shares in the company, valued at approximately $167,757. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Christopher Causey sold 590 shares of the firm’s stock in a transaction that occurred on Thursday, July 6th. The stock was sold at an average price of $132.61, for a total transaction of $78,239.90. Following the sale, the director now owns 3,875 shares of the company’s stock, valued at approximately $513,863.75. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,499 shares of company stock valued at $2,905,101. 7.80% of the stock is currently owned by company insiders.

About United Therapeutics Corporation

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.